Biotricity Inc (BTCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotricity Inc (BTCY) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($415.63K) by net assets ($-31.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BTCY net asset quality index to measure how much of total assets are equity-financed.
Biotricity Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Biotricity Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Biotricity Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Biotricity Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotricity Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Golden Metal Resources PLC
LSE:GMET
|
-0.027x |
|
NORTHERN SHIELD RES INC.
F:N9SA
|
N/A |
|
NetJobs Group AB
ST:NJOB
|
-0.675x |
|
Renegade Exploration Ltd
AU:RNX
|
-0.170x |
|
Primarindo Asia Infrastructure Tbk PT
JK:BIMA
|
0.100x |
|
Science Group plc
LSE:SAG
|
0.034x |
|
ASA International Group PLC
LSE:ASAI
|
0.234x |
|
STL Global Limited
NSE:SGL
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Biotricity Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Biotricity Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Biotricity Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-30.01 Million | $-2.38 Million | 0.079x | -64.49% |
| 2024-03-31 | $-29.98 Million | $-6.69 Million | 0.223x | -67.29% |
| 2023-03-31 | $-19.85 Million | $-13.55 Million | 0.683x | -90.34% |
| 2022-03-31 | $-2.14 Million | $-15.16 Million | 7.070x | +335.99% |
| 2021-03-31 | $-6.83 Million | $-11.08 Million | 1.622x | -38.12% |
| 2020-03-31 | $-3.00 Million | $-7.86 Million | 2.621x | -10.77% |
| 2019-03-31 | $-1.78 Million | $-5.22 Million | 2.937x | +110.44% |
| 2018-03-31 | $173.25K | $-4.87 Million | -28.136x | -3390.93% |
| 2017-03-31 | $-4.38 Million | $-3.75 Million | 0.855x | -46.06% |
| 2016-03-31 | $-1.24 Million | $-1.96 Million | 1.585x | +139.05% |
| 2015-03-31 | $340.00K | $-1.38 Million | -4.059x | -17150.20% |
| 2014-03-31 | $349.44K | $-8.22K | -0.024x | -- |
About Biotricity Inc
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes … Read more